Product
Veterinary / PRODUCT
HOME>Product>Animal Health>Veterinary
Oclacitinib
| Other Name | JAKi; PF 03394197; trans-N-Methyl-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclohexanemethanesulfonamide | |
| Product Name | Oclacitinib | |
 | ||
| Structure |  | |
| Molecular | C15H23N5O2S | |
| M.Weight | 337.44 | |
| CAS | 1208319-26-9 | |
- Tel: +86-532-83876123
- Fax: +86-532-83876157
- Email: dennis@qingmeibio.com
- Skype: dennis10221
CHEMCIAL PROPERTY
Oclacitinib maleate is an oral, selective Janus kinase (JAK)-1 and JAK-3 inhibitor approved for treatment of hypersensitivity-induced cutaneous pruritus in dogs 12 months of age or older.
CLINICAL APPLICATIONS
Oclacitinib inhibits activity of pruritogenic, proinflammatory cytokines (eg, interleukin-2 [IL-2], IL-4, IL-6, IL-13, IL-31) via JAK-1 and JAK-3 inhibition.
IL-31 is a mediator of canine pruritus.
Oclacitinib offers rapid pruritus control of canine hypersensitivity syndromes without the adverse effects associated with glucocorticoids.
CLINICAL APPLICATIONS
Oclacitinib inhibits activity of pruritogenic, proinflammatory cytokines (eg, interleukin-2 [IL-2], IL-4, IL-6, IL-13, IL-31) via JAK-1 and JAK-3 inhibition.
IL-31 is a mediator of canine pruritus.
Oclacitinib offers rapid pruritus control of canine hypersensitivity syndromes without the adverse effects associated with glucocorticoids.
TECHNICAL DATA
DOCUMENT SERVICE